References
1 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
2 Lei WT, Chang LS, Zeng BY, et al. Pharmacologic interventions for Kawasaki disease in children: a network meta-analysis of 56 randomized controlled trials[J]. EBioMedicine, 2022, 78: 103946. PMID: 35306339. PMCID: PMC8933672. DOI: 10.1016/j.ebiom.2022.103946.
3 Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review[J]. Antonie Van Leeuwenhoek, 2020, 113(12): 2019-2040. PMID: 33136284. DOI: 10.1007/s10482-020-01474-7.
4 Dai Y, Shen Z, Khachatryan LG, et al. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: a comprehensive review[J]. Pathol Res Pract, 2023, 249: 154740. PMID: 37567034. DOI: 10.1016/j.prp.2023.154740.
5 Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure[J]. Nat Rev Cardiol, 2019, 16(3): 137-154. PMID: 30410105. PMCID: PMC6377322. DOI: 10.1038/s41569-018-0108-7.
6 Felizardo RJF, Watanabe IKM, Dardi P, et al. The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids[J]. Pharmacol Res, 2019, 141: 366-377. PMID: 30639376. DOI: 10.1016/j.phrs.2019.01.019.
7 Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease[J]. Arthritis Care Res (Hoboken), 2022, 74(4): 538-548. PMID: 35257507. DOI: 10.1002/acr.24838.
8 Chen J, Yue Y, Wang L, et al. Altered gut microbiota correlated with systemic inflammation in children with Kawasaki disease[J]. Sci Rep, 2020, 10(1): 14525. PMID: 32884012. PMCID: PMC7471315. DOI: 10.1038/s41598-020-71371-6.
9 Tamburini S, Shen N, Wu HC, et al. The microbiome in early life: implications for health outcomes[J]. Nat Med, 2016, 22(7): 713-722. PMID: 27387886. DOI: 10.1038/nm.4142.
10 林瑶, 李晓惠, 石琳, 等. 2017年版《川崎病的诊断、治疗及远期管理——美国心脏协会对医疗专业人员的科学声明》解读[J]. 中国实用儿科杂志, 2017, 32(9): 641-648. DOI: 10.19538/j.ek2017090601.
11 Zeng Q, Zeng R, Ye J. Alteration of the oral and gut microbiota in patients with Kawasaki disease[J]. PeerJ, 2023, 11: e15662. PMID: 37456866. PMCID: PMC10340105. DOI: 10.7717/peerj.15662.
12 Ahearn-Ford S, Berrington JE, Stewart CJ. Development of the gut microbiome in early life[J]. Exp Physiol, 2022, 107(5): 415-421. PMID: 35041771. PMCID: PMC9305283. DOI: 10.1113/EP089919.
13 Milani C, Duranti S, Bottacini F, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota[J]. Microbiol Mol Biol Rev, 2017, 81(4): e00036-17. PMID: 29118049. PMCID: PMC5706746. DOI: 10.1128/MMBR.00036-17.
14 Kaneko K, Akagawa S, Akagawa Y, et al. Our evolving understanding of Kawasaki disease pathogenesis: role of the gut microbiota[J]. Front Immunol, 2020, 11: 1616. PMID: 32793240. PMCID: PMC7393004. DOI: 10.3389/fimmu.2020.01616.
15 Rowley AH. Is Kawasaki disease an infectious disorder?[J]. Int J Rheum Dis, 2018, 21(1): 20-25. PMID: 29105346. PMCID: PMC5777874. DOI: 10.1111/1756-185X.13213.
16 Tsoukas P, Yeung RSM. Kawasaki disease-associated cytokine storm syndrome[J]. Adv Exp Med Biol, 2024, 1448: 365-383. PMID: 39117827.DOI: 10.1007/978-3-031-59815-9_25.
17 Esposito S, Polinori I, Rigante D. The gut microbiota-host partnership as a potential driver of Kawasaki syndrome[J]. Front Pediatr, 2019, 7: 124. PMID: 31024869. PMCID: PMC6460951. DOI: 10.3389/fped.2019.00124.
18 沈男, 王莹, 王兴翠, 等. 川崎病对儿童肠道菌群的影响[J]. 基础医学与临床, 2019, 39(5): 636-640. DOI: 10.3969/j.issn.1001-6325.2019.05.005.
19 Fiore E, Van Tyne D, Gilmore MS. Pathogenicity of Enterococci[J]. Microbiol Spectr, 2019, 7(4): 10.1128/microbiolspec.gpp3-0053-2018. PMID: 31298205. PMCID: PMC6629438. DOI: 10.1128/microbiolspec.GPP3-0053-2018.
20 Wu WL, Adame MD, Liou CW, et al. Microbiota regulate social behaviour via stress response neurons in the brain[J]. Nature, 2021, 595(7867): 409-414. PMID: 34194038. PMCID: PMC8346519. DOI: 10.1038/s41586-021-03669-y.
21 Agbavor C, Zimnicka A, Kumar A, et al. The chaperone PrsA2 regulates the secretion, stability, and folding of listeriolysin O during Listeria monocytogenes infection[J]. mBio, 2024, 15(7): e0074324. PMID: 38809022. PMCID: PMC11253611. DOI: 10.1128/mbio.00743-24.
22 Skrobas U, Zie WS, Bielewicz J, et al. The rapidly progressing and fatal outcome of rhombencephalitis by listeriosis in a 61-year-old male[J]. Ann Agric Environ Med, 2024, 31(2): 311-314. PMID: 38940119. DOI: 10.26444/aaem/178178.
23 Wing EJ, Gregory SH. Listeria monocytogenes: clinical and experimental update[J]. J Infect Dis, 2002, 185 Suppl 1: S18-S24. PMID: 11865436. DOI: 10.1086/338465.
24 Ling Z, Zhao D, Xie X, et al. inlF enhances Listeria monocytogenes early-stage infection by inhibiting the inflammatory response[J]. Front Cell Infect Microbiol, 2022, 11: 748461. PMID: 35223532. PMCID: PMC8866704. DOI: 10.3389/fcimb.2021.748461.
25 Shen J, Ding Y, Yang Z, et al. Effects of changes on gut microbiota in children with acute Kawasaki disease[J]. PeerJ, 2020, 8: e9698. PMID: 33005487. PMCID: PMC7512135. DOI: 10.7717/peerj.9698.
26 Teramoto Y, Akagawa S, Hori SI, et al. Dysbiosis of the gut microbiota as a susceptibility factor for Kawasaki disease[J]. Front Immunol, 2023, 14: 1268453. PMID: 38022552. PMCID: PMC10644744. DOI: 10.3389/fimmu.2023.1268453.
27 Khan I, Li XA, Law B, et al. Correlation of gut microbial compositions to the development of Kawasaki disease vasculitis in children[J]. Future Microbiol, 2020, 15: 591-600. PMID: 32490694. DOI: 10.2217/fmb-2019-0301.